Editorial board member John Wilding discusses the lessons for healthcare professionals from the SGLT2 inhibitor cardiovascular outcome trials about the benefits and drawbacks of the medication class. <a title="SGLT2 inhibitors: The story so far" href= "http://bit.ly/Wilding-SGLT2is-podcast" target="_blank" rel= "noopener">Find more on Medicine Matters diabetes</a> This content was originally published on Medicine Matters diabetes (<a href= "https://diabetes.medicinematters.com">https://diabetes.medicinematters.com</a>) on September 8, 2017.

Editorial board member John Wilding discusses the lessons for healthcare professionals from the SGLT2 inhibitor cardiovascular outcome trials about the benefits and drawbacks of the medication class. Find more on Medicine Matters diabetes This content was originally published on Medicine Matters diabetes (https://diabetes.medicinematters.com) on September 8, 2017.

Editorial board member John Wilding discusses the lessons for healthcare professionals from the SGLT2 inhibitor cardiovascular outcome trials about the benefits and drawbacks of the medication class. <a title="SGLT2 inhibitors: The story so far" href="http://bit.ly/Wilding-SGLT2is-podcast" rel="noopener noreferrer">Find more on Medicine Matters diabetes</a> This content was originally published on Medicine Matters diabetes (<a href="https://diabetes.medicinematters.com" rel="noopener noreferrer">https://diabetes.medicinematters.com</a>) on September 8, 2017.

Share SGLT2 inhibitors: The story so far (with John Wilding)

Sign up to save your podcasts

SGLT2 inhibitors: The story so far (with John Wilding)

SGLT2 inhibitors: The story so far (with John Wilding)